IDSA GUIDELINES Bundle (free trial)

Leishmaniasis

IDSA GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/774306

Contents of this Issue

Navigation

Page 26 of 39

27 FDA Approval Comments Yes, but not for ML (off-label use) Yes, but not for ML (off-label use) Yes, approved for ML caused by L. (V.) braziliensis Target dose is ~2.5 mg/kg/day, but doses >150 mg/day have not been studied. GI side effects may limit higher doses. See Table 4 and Recs. 78–79. No, but available in the US under a CDC- sponsored IND protocol. • Supplied as 100 mg Sb V /mL. • Dilute dose in D5W (~50–100 mL) for IV, ~10–30-minute infusion. • Use of an in-line filter is recommended. No. In US, would require investigator- sponsored IND protocol. • Supplied as 81 mg Sb V /mL. • Dilute dose in D5W (~50–100 mL) for IV, ~10–30-minute infusion. Yes, but not for ML (off-label use)

Articles in this issue

Archives of this issue

view archives of IDSA GUIDELINES Bundle (free trial) - Leishmaniasis